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Summary Results of plasma or urinary amino acids are
used for suspicion, confirmation or exclusion of diag-
nosis, monitoring of treatment, prevention and progno-
sis in inborn errors of amino acid metabolism. The
concentrations in plasma or whole blood do not
necessarily reflect the relevant metabolite concentra-
tions in organs such as the brain or in cell compart-
ments; this is especially the case in disorders that are not
solely expressed in liver and/or in those which also
affect nonessential amino acids. Basic biochemical
knowledge has added much to the understanding of
zonation and compartmentation of expressed proteins
and metabolites in organs, cells and cell organelles. In
this paper, selected old and new biochemical findings in
PKU, urea cycle disorders and nonketotic hyperglyci-
naemia are reviewed; the aim is to show that integrating
the knowledge gained in the last decades on enzymes
and transporters related to amino acid metabolism
allows a more extensive interpretation of biochemical
results obtained for diagnosis and follow-up of patients
and may help to pose new questions and to avoid
pitfalls. The analysis and interpretation of amino acid
measurements in physiological fluids should not be
restricted to a few amino acids but should encompass
the whole quantitative profile and include other path-
ophysiological markers. This is important if the patient
appears not to respond as expected to treatment and is
needed when investigating new therapies. We suggest
that amino acid imbalance in the relevant compart-
ments caused by over-zealous or protocol-driven treat-
ment that is not adjusted to the individual patient_s
needs may prolong catabolism and must be corrected.
Abbreviations
IEM inborn error of metabolism
PKU Phenylketonuria
UC urea cycle
UCD urea cycle disorder
NKH nonketotic hyperglycinaemia
LNAA large neutral amino acid
Introduction
It is obvious that patients, organs or cells are not
homogeneous with respect to protein and metabolite
concentrations; knowledge of compartmentation and
zonation is implied when in daily practice we use
results of enzymes assayed in plasma for medical
decisions as indicators of tissue damage (e.g. CK-MB,
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ALAT, ASAT), but the basic knowledge of the tissue
expression of these proteins and isoforms is not always
consciously kept in mind. In inborn errors of metab-
olism (IEMs) such knowledge of compartmentation
should be taken into account when interpreting con-
centrations of small molecules such as amino acids,
lactate, pyruvate or carnitine(s) because clinical symp-
toms are not sufficient to allow decisions to be made.
Results of concentration measurements in whole
blood are not equal to plasma results even if the solute
concentration is the same in the aqueous space of
plasma and red cell. This is due to the volume
occupied by plasma proteins (and proteins from
haemolysed red cells) in the fixed sample volume. In
plasma this amounts to õ7%; in whole blood the
protein displacement is about 17–19% of the sample
volume at a haematocrit of 0.45. The amount of solute
measured is expressed per sample volume in both
instances but the aqueous volume differs. This effect is
common knowledge for glucose measurements and
different decision limits of glucose concentration are
used for diagnosing diabetes depending on the sample
analysed (6.3 mmol/L in whole blood and 7.0 mmol/L
in plasma). Whole-blood concentrations are thus
influenced by the haematocrit. In neonates with a
widely variable haematocrit this effect is even more
pronounced, a fact well known to the neonatal
screening specialists who assume a haematocrit of
0.55 for calibration.
The same principle applies to amino acids and other
small molecules; in consequence it is necessary to
indicate the sample type (and method) used to allow
interpretation and correct comparison with data from
the literature including decision or reference limits
when reporting results. As for glucose, the time delay
between the last food intake and sampling affects the
plasma results and must be reported. However, this
information is not always given in publications of
metabolite results. With acylcarnitines the interpreta-
tion is further complicated by the differences of
concentration and pattern between plasma and red
cell acylcarnitines which contribute to the results
obtained from dried blood spots.
For many IEMs, direct extrapolations from plasma
concentration of amino acids to the underlying patho-
genic process can be misleading if one does not take
into account the many mechanisms modifying amino
acid concentrations between the location where pathol-
ogy occurs and the metabolite result in the sample
analysed. In the majority of IEMs there are still gaps in
knowledge in the vast puzzle of regulatory mechanisms
intervening within cells, between cells and between
different cell types of organs, leading to a diversity of
expression within and between organs. Thus, awareness
of basic knowledge in physiological and pathological
biochemistry is needed in order to avoid pitfalls and
appreciate the limits of interpretation imposed on us
when we try to understand patterns of amino acids in
plasma or other markers of intermediary metabolism.
Recent or sometimes neglected older biochemical
findings in classic phenylketonuria (PKU), urea cycle
disorders (UCDs) and nonketotic hyperglycinaemia
(NKH) are reviewed, and their potential impact is
discussed.
Phenylketonuria
The success of newborn screening by the Guthrie test
and dietary restriction of the essential amino acid
phenylalanine—complemented by special amino acid
mixtures devoid of phenylalanine—has directed re-
search in PKU mainly towards questions related to the
optimization and evaluation of treatment. Relatively
few questions about phenylalanine toxicity to the brain
have been addressed (238 publications on pathophys-
iology out of 13 800 on PKU up to 2007).
Noncompliance with treatment and neurological
symptoms in postpubertal patients revived interest in
old findings: Using the bolus injection technique
Oldendorf and colleagues (Oldendorf et al 1971) had
tested an earlier hypothesis (Appel 1966) that there is
competition between large neutral amino acids
(LNAAs) for brain uptake from the blood. They found
that selenomethionine uptake in PKU patients was
decreased by high phenylalanine concentrations in
plasma. Kinetic data of the L1 transporter that is
expressed on the luminal membrane of brain capillary
endothelium were later established in non-anaesthetized
rats (Miller et al 1985); the data supported Oldendorf_s
findings.
Large neutral amino acids and phenylalanine in brain
Because neurological symptoms were manifested after
discontinuing the diet or because phenylalanine con-
centration in plasma increased owing to noncompli-
ance in adolescent PKU-patients, the Glostrup group
proposed alternative treatments with addition of
LNAAs (Gu¨ttler and Lou 1986; Lou et al 1985).
Following that lead, Pietz and colleagues (1999) inves-
tigated the effect of peroral administration of LNAAs
on the transport of phenylalanine into the brain in
vivo. They administered an acute phenylalanine load
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(100 mg/kg) to PKU patients with or without added
LNAAs (150 mg/kg). Brain phenylalanine was quanti-
fied in vivo by proton magnetic resonance spectrosco-
py at 1.5 tesla simultaneously with the sampling for
plasma amino acids up to 24 h post load. In addition, I
calculated the uptake velocity from the plasma con-
centrations of phenylalanine and the other LNAAs
competing for the L1 transporter from the published
data (Pietz et al 1999). The co-application of LNAAs
blocked the post-load rise of the already increased
phenylalanine concentrations in vivo in the brain
(Table 1) as compared with the increase found in
patients without co-application of LNAAs. In contrast
to the measured brain concentrations, the calculated
uptake velocity of phenylalanine remained excessively
high and dropped only slightly on addition of LNAAs.
Interestingly, co-administration of LNAAs consis-
tently prevented the EEG frequency changes (increase
of theta activity and decrease of alpha2 activity) found
up to 24 h after load in the PKU patients receiving the
phenylalanine load alone. As noted by the authors, the
effect of the load on the EEG cannot be explained by
the competition for uptake at the blood–brain barrier
alone. Brain uptake velocity from an arterial bolus
does not equal net transport into and out of the brain
or its cellular compartments. Amino acid transporters
at the abluminal membrane of the capillary endothelia
exporting amino acids out of the brain (see below),
and plasma membrane transporters of the glia and
neurons modify the net transport of amino acids (for a
review see Hawkins et al 2006).
Brain uptake velocity of leucine
In addition to the effect of co-administration of LNAAs
on the EEG and on in vivo brain concentrations of
phenylalanine, one can further ask whether the co-
administration of LNAAs as applied by Pietz and
colleagues (1999) normalized the influx of competing
LNAAs in the brain and especially of leucine, a high-
affinity substrate for the L1 transporter. Recent
findings show that leucine plays a role not only as a
substrate for protein synthesis but also as a signalling
molecule for translation initiation (mTor complex, see
below). Taub and Johnson (1975) had observed that
phenylalanine injections led to polyribosome disaggre-
gation in the brain in neonatal mice and concluded
that Fthe monomeric (80S) ribosomes were inactive ...
with regard to protein synthesis_.
Current MRS techniques (at 1.5 T) are not sensitive
enough to measure physiological or even decreased
concentrations of LNAAs in the low micromolar range
and no in vivo data on the brain concentrations of
leucine in PKU patients are available to our knowledge.
Despite the fact that high brain concentrations of
phenylalanine correlated poorly with the calculated
uptake velocity (Table 1), the uptake velocity of leucine
was calculated from the reported amino acid plasma
concentrations by using the same kinetic variables
(Miller et al 1985) of the L1 system as Pietz and
colleagues (1999). The uptake velocity of leucine in
PKU patients remained below the control values as
shown in Table 1 except when the LNAAs were at peak






Phe Leu v-Phe v-Leu
Plasma concentration (mmol/L)a Calculated brain uptake velocity
(mmol/min per kg tissue)b
Phe 0 252 1036 136 57.2 7.0
Phe 6 344 1890 120 95.9 5.9
Phe 12 377 1838 135 93.4 6.6
Phe 24 397 1693 109 87.1 5.4
Phe + LNAAs 0 226 1063 146 58.2 7.5
Phe + LNAAs 6 235 1887 398 92.7 19.1
Phe + LNAAs 12 210 1669 338 82.7 16.3
Phe + LNAAs 24 309 1755 115 88.8 5.6
Controlsa 0 40–70 75–170 6.0 9.4
Phe, phenylalanine; Leu, leucine; v, velocity; LNAA, large neutral amino acid.
a Data from Pietz et al (1999).
b Calculated brain uptake velocity.
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level with leucine concentrations above 340 mmol/L
(reference values of healthy adults, 75–170 mmol/L).
With the average plasma data on 10 adult controls of
Pietz and colleagues (1999), an uptake velocity for
leucine of 9.4 nmol/min per g was obtained. As shown
in Fig. 1, the uptake velocity of leucine in normal
babies aged 4 months sampled around trough level are
mostly above 6 nmol/min per g). These were computed
from amino acid concentrations found in plasma taken
at the times indicated (E. Haschke-Becher and C.
Bachmann, personal observation). The findings indi-
cate that the LNAA supplements co-administered with
the load do not correct the leucine uptake, most likely
due to competition by the high plasma phenylalanine
concentration, except perhaps at the peak level of
LNAAs, when their concentrations are markedly
increased.
Accordingly, knowledge of leucine concentration in
brain and transport kinetics would be of interest for
assessing whether low leucine impairs protein synthesis
in the developing brain and contributes to the irre-
versible symptoms of PKU. Unfortunately, in vivo
brain measurements of phenylalanine were not done in
a recent pilot experiment of chronic application of
LNAAs to PKU (Koch et al 2003). In vitro data of
leucine concentrations in brain were not reported for
PKU-mice (ENU mutation) fed LNAAs supplements
(Matalon et al 2003).
Thus, it remains open whether leucine is decreased
in untreated PKU in the brain, and whether long-term
LNAA co-supplementation avoids low leucine concen-
trations in the different cells of the developing brain in
PKU which could slow or impair protein synthesis. The
use of 7.6 T MRS instruments with animal models
might perhaps allow this to be determined in the
future.
Recently a commercial product for peroral applica-
tion of a supplement of LNAAs (and arginine) was
evaluated in a pilot experiment on 20 PKU patients
(Matalon et al 2006, 2007). The aim was to reduce the
uptake of phenylalanine into the intestine. The follow-
ing transporters are probably involved (Berger et al
2000; Verrey et al 2004): on the apical side of the
intestinal epithelia system b0,+ and System B0, and on
the basolateral side system y+L and system L; this
occurs in conjunction with the exchange of LNAAs
with arginine by the cationic amino acid transport
systems b0,+and y+L. Matalon et al (2006, 2007)
reported a decline of phenylalanine concentration in
plasma of the patients; however, sampling was done on
average 2 h postprandially. The results of these authors
merely indicate that the intestinal absorption of phenyl-
alanine could be reduced at around the time of peak
absorption of the intestine, but no data were given on
trough concentration of phenylalanine or on the area
under the time–concentration curve during absorption.
No data on the other LNAAs were shown. Thus we
cannot estimate whether in humans such a diet will affect
transport into the brain and whether, for example,
transport of leucine, tryptophan and tyrosine into organs
(including the brain) will be sufficient for such a
treatment of PKU patients.
Urea cycle disorders
The follow-up of patients with urea cycle disorders
(UCDs) includes frequent monitoring of plasma ammo-
nia and amino acids in order to adapt the treatment to the
individual requirements of each patient. In the plasma
samples of such patients, glutamine concentrations at the
upper limit of reference and low-branched-chain amino
acid (BCAA) concentrations are often found. In adults
with hepatic insufficiency or cirrhosis, low-branched chain
amino acid concentrations in plasma are well known. We
will focus on glutamine and its connection to BCAAs.
Glutamine has a central position in intermediary
metabolism:
(1) It is a substrate for synthesis of the purines
(phosphoribosylpyrophosphate (PRPP) amido-
transferase), pyrimidines (carbamylphosphate
synthetase2 trifunctional complex), amino sugars,
asparagine, NAD and GMP and thus especially
important for tissues with high turnover like the
mucosa of the intestinal tract or in cell cultures.
(2) Glutamine synthesis from ammonia and gluta-
mate catalysed by glutamine synthase is active in
most major organs; glutamine synthase is not
expressed in neurons. Glutamine is a vehicle for
Fig. 1 Brain uptake velocity of leucine calculated from plasma
data of normal babies (age 4 months) against the sampling delay
after the end of the last food intake
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transporting amino- and amido-nitrogen and fuel
between organs, cells and cell organelles and links
the Krebs cycle to the urea cycle.
(3) In the liver glutamine synthesis (high affinity but low
capacity for ammonia) is restricted to a small
pericentral zone of the acini, together with the
mitochondrial ornithine aminotransferase and the
mitochondrial membrane transporter importing
ornithine into the mitochondria in exchange with
H+ (Dingemanse et al 1996; Gebhardt et al 2007;
Ha¨ussinger 1983; Jungermann and Kietzmann
1996). In contrast, the three urea cycle enzymes
involved in the mitochondrial detoxification of
ammonia are located in the periportal zones of the
liver acini as well as the cytosolic enzymes of the
urea cycle (and the mitochondrial membrane trans-
porter which imports ornithine into the mitochon-
dria in exchange for citrulline). This localization in
the entry zone of the portal blood allow detoxifica-
tion of the bulk of ammonia originating from the
splanchnic bed to urea, while the pericentral zone is
the second line of defence generating glutamine.
Urea cycle enzymes are also expressed in the
intestinal tract (at a lower activity than in liver)
where postnatally the enzymes mainly catalyse
citrulline production from intestinal glutamine. At
the cellular level the study of patients with trans-
porter defects (ornithine transporter deficiency
leading to HHH-syndrome, citrin deficiency, and
lysinuric protein intolerance) has been useful for
validating in vitro results of basic research on the
affected transporters of the mitochondrial mem-
brane, or the basolateral membrane intestinal and
renal epithelia (Palmieri 2004).
(4) The kidney is the main organ for excretion of
waste nitrogen, mainly as urea-N (80–90% of
total N). Glutamine is excreted into the urine or
deaminated to glutamate and ammonia by gluta-
minase, which is stimulated by acidosis (Nissim
1999; Welbourne 1987). After transport into the
renal tubule NH3 is trapped as NH
þ
4 in the acidic
urine. Argininosuccinate synthetase and lyase are
expressed in the cortical part of the kidney
tubules while arginase2 is mainly expressed in
the medullary part (Miyanaka et al 1998). This
zonation might be relevant for the guanidinoace-
tate synthesis from arginine and glycine.
Glutamine concentration in plasma
The glutamine concentration in plasma at steady state
results from the sum of cytosolic concentrations in the
cells of the respective organs and tissues and from the
activity of the glutamine plasma membrane transport-
ers. For each organ and tissue, glutamine concentration
depends on its synthesis by glutamine synthase and the
cytosolic concentrations of ammonia, glutamate and
ATP; on its utilization as substrate; on its transport into
the mitochondria; on its breakdown to glutamate
(catalysed by glutaminases); and on the transport across
the plasma membranes (Curthoys and Watford 1995;
Labow et al 2001; Nissim 1999). The major sites for
glutamine synthesis are the muscle, lung, liver and
adipocytes (Curthoys and Watford 1995). An impor-
tant proportion of muscle glutamate nitrogen (up to
50%) originates from branched-chain amino acids
(Chang and Goldberg 1978).
During hyperammonaemia in experimental animals
and adult patients the increase in plasma of glutamine
parallels the decrease of BCAAs (Leweling et al 1996);
this cannot be explained by hyperinsulinism alone,
which stimulates the transport of BCAAs into cells
and delays the intracellular depletion of BCAAs. The
transamination of BCAAs to form glutamate in the
mitochondria is catalysed by the branched-chain
aminotransferase (mBCAT; muscle > adipose tissue >
brain and other tissues). The biochemistry of this
enzyme has been studied intensively by the group of
Hutson (Bixel et al 2001; Hall et al 1993; Hutson et al
1992, 1998, 2001). mBCAT appears also to stimulate
the export of a-ketoisocaproate (KICA) out of the
mitochondrion, and to maintain a low intramitochon-
drial concentration of KICA favouring the transami-
nation of leucine. Furthermore, mBCAT forms a
supramolecular complex in mitochondria by associa-
tion with the E1 unit of branched-chain keto acid
dehydrogenases, and thus allows channelling of KICA
into this irreversible step of BCAA degradation (Islam
et al 2007).
Thus when glutamine synthesis is increased in the
peripheral organs for ammonia detoxification and/or
consumed for conjugation with phenylacetate and
phenylbutyrate (in the liver and kidney), more gluta-
mate is utilized; in consequence, BCAA will decrease
in the cells and then in plasma.
It has been known for years that acute hyper-
ammonaemia blocks protein synthesis. A possible
mechanism has recently been unravelled: leucine is
not only an essential substrate for protein synthesis but
also a signalling molecule for translation initiation by
stimulating mTor (for details see Codogno and Meijer
2005; Harris et al 2006; Meijer and Dubbelhuis 2004;
Nishitani et al 2004; Proud 2004a, b; Rennie et al 2004;
Yoshizawa 2004). The characteristics have been stud-
ied in vitro; the in vivo cellular concentration in
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different human tissues at which leucine limits protein
synthesis has not been defined, to our knowledge. It
can be speculated that persistently low plasma leucine
concentration will prolong catabolism in patients and
limit protein synthesis if the tissue concentrations of
leucine are chronically decreased.
Another mechanism which might modulate the activ-
ity of mTor is mediated by the insulin-like growth factors
(IGFs). A leucine-deficient diet leads to decreased free
IGF in rats (IGF 1 and 2). The more pronounced
expression of the IGF binding protein1 than of the
IGF1 leads to a decrease of the free fractions (Bruhat
et al 1999; Endo et al 2002; Jousse et al 1998). These
chronic in vivo experiments support the hypothesis that
low leucine supply inhibits protein synthesis, because
free IGF1 acts finally on mTor via the insulin receptor
substrate.
Glutamine metabolism in brain
Compartmentation of glutamine metabolism and
transport in brain is rather complex as shown in
Fig. 2. Brain expresses a special isoform of glutamate
dehydrogenase (encoded by GLUD2) which is more
sensitive to leucine activation in presence of ADP than
the housekeeping (GLUD1-encoded) enzyme and much
less sensitive to GTP inhibition (Plaitakis et al 2003); this
might be relevant for understanding the pathogenesis of
the hyperinsulinism–hyperammonaemia syndrome.
Another isoform which is mainly expressed in brain
concerns BCAA metabolism: In addition to the
mitochondrial isoform of BCAT, a second cytosolic
isoform (cBCAT) has been characterized (Sweatt et al
2004). This is mainly found in glutamatergic axon
terminals of the cortex and also in GABAergic cell
bodies; it is inhibited by gabapentin. The glutamine/
glutamate shuttle between astrocytes and neurons is well
known (Bak et al 2006). An analogous cycle for
branched-chain amino acids has been proposed
(Brosnan and Brosnan 2006; Hutson et al 2001; Yudkoff
et al 2005). By coupling the two shuttles between
astrocytes (mitochondrial BCAT and cytosolic glutamine
synthase) and neurons (cytosolic BCAT and kidney type
mitochondrial glutaminase), this compartmentation
could allow replenishment of the glutamate in the axon
terminals after high glutamatergic activity. Moreover, the
Fig. 2 Simplified scheme of the glutamine/glutamate and leucine
shuttles and connection to the brain capillary endothelia. Abbre-
viations: NH3, ammonia/ammonium; GLU, glutamate; GLN,
glutamine; KG, a-ketoglutarate; Leu, leucine; KICA, a-ketoiso-
caproate; GABA, g-aminobutyrate; SSA, succinate semialdehyde;
SUC, succinate (Krebs cycle); gGT, g–glutamyltranspeptidase;
GSH, glutathione; PG, pyroglutamate (gamma-glutamyl cycle
intermediate); Gly, glycine; Cys, cystein; AA, amino acid.
Enzymes and amino acid transporters: 1, Glutamine synthase
(cytosolic). 2, Glutaminase (kidney type; inner mitochondial
membrane). 3, Glutamate decarboxylase. 4, Glutamate dehydro-
genases (mitochondrial); two isoforms: GLUD1 derived , house-
keeping enzyme and GLUD2 derived, brain-specific, less sensitive
to GTP inhibition, stimulated by lower leucine + ADP concen-
trations than the housekeeping enzyme; for details see Plaitakis
et al (2003). 5, Branched-chain aminotransferase, mitochondrial
isoform (mBCAT). 6, Branched-chain aminotransferase, cytosol-
ic isoform (cBCAT) mainly expressed in brain (see text). 7,
Glutamate transporters EAAT1 (= GLAST), EAAT2 (= GLT1).
8, Mitochondrial glutamate transporter (inhibited by histidine)
(Pichili et al 2007). 9, SNAT3 (= SN1) main glutamine
transporter at astrocyte membrane, sodium-dependent. 10,
System N subfamily, sodium dependent (SNAT3 = SN1). 11,
System A transporter, sodium-dependent (SNAT1 (? = GlnT;
NAT1). 12, Aminotransferases. 13, Facilitative transporters at
the luminal membrane L-system (LAT1). 14, Abluminal gluta-
mate transporters EAAT1–3, sodium-dependent. For further
information: on blood–brain barrier transport of amino acids
and alias of transporter denomination, see. Chen et al (2004),
Hawkins et al (2006), Kanai and Hediger (2004), Mackenzie and
Erickson (2004), Orlowski and Grinstein (2004), Palacin and
Yoshikatsu (2004), Palmieri (2004), Verrey et al (2004)
12 J Inherit Metab Dis (2008) 31:7–20
combined shuttles function as intercellular ammonia
transporter by the transport of amino groups.
The brain depends on the supply of energy and
amino acids from the systemic circulation; in addition
it must be able to export waste nitrogen. Since the
mitochondrial urea cycle enzymes are not expressed in
brain, other pathways are used. The many transporters
of the capillary endothelia (blood–brain barrier) allow
a controlled uptake of amino acids into the brain and
net removal of acidic and nitrogen-rich amino acids
(such as glutamine). The brain capillary endothelia are
spatially polarized: the g-glutamyl cycle is expressed on
the luminal side and the various amino acid trans-
porters on the luminal and abluminal side differ as
shown in Fig. 2 (Hawkins et al 2006).
Twenty per cent to fifty per cent of ammonia is
taken up from capillary blood into the brain. Ammo-
nia is considered to enter the brain by diffusion; the
quantitative role of aquaporins in vivo is not clear
(Marcaggi and Coles 2001). In contrast, glutamine
uptake from plasma into the capillary endothelia is
minor and the glutamine concentration is not really
dependant on plasma glutamine concentration. Gluta-
mine has a very low affinity for the facilitative
transporter for uptake at the luminal membrane and
for g-glutamyl transpeptidase. The velocity of gluta-
mine brain uptake in vivo at very high plasma
concentrations of glutamine and low concentrations
of LNAAs is not known. Glutamine in the brain is to a
large extent newly synthesized in astrocytes. The
transporters of the brain capillary endothelia are
organized in such a way as to export glutamine and
glutamate from the extracellular fluid of the brain into
the capillary endothelia where glutamine is efficiently
hydrolysed by glutaminase to glutamic acid. This is
either exported or transaminated and the nitrogen is
exported as amino acids by facilitative transporters at
the luminal membrane (for further details see Fig. 2
and Hawkins et al 2006). Interestingly, Lee and
colleagues (1996) and Hawkins and colleagues (2006)
indicated that pyroglutamic acid (a metabolite of the
g-glutamyl cycle) stimulated the sodium-dependent
amino acid transporters of the abluminal membrane
of the capillary endothelia (except for the system N
subfamily transporter). In 1986 we had found that the
uptake of tryptophan was stimulated by pre-incubation
of brain capillary endothelia with 10 mmol/L L- or
D-glutamine, but was reduced by inhibitors of g-
glutamyl transferase (acivicin) or of g-glutamylcysteine
synthase such as buthionine or methionine sulfoxi-
mine; however, we found no clue to explain the
mechanism (for details see Bachmann (1992, 2002)).
The stimulation of the abluminal transporters by
pyroglutamic acid mentioned above could now explain
our findings.
To our knowledge, the quantitative contribution of
the choroid plexus (which expresses a system N
subfamily transporter and the g-glutamyl cycle) to the
export of glutamine into the CSF has not been assessed
in vivo.
The biochemical characterization of transporters
and enzymes and of their compartmentation in the
brain has opened many questions which need in vivo
confirmation in animal models. Brain uptake of amino
acids by the facilitative L1 and the cationic trans-
porters can be measured; but the detailed fluxes in
vivo in the many compartments of the brain including
the capillary endothelia cannot be derived from the in
vitro data determined under artificial conditions with
isolated enzymes and transporters. Interactions be-
tween compartments, not only substrate concentra-
tions, should be taken into account; additional
variables interfere such as ion gradients (protons,
sodium, potassium), membrane potentials, surface
density of transporters and glutamatergic activity of
the neurons. To our knowledge, computer modelling
of fluxes has so far been restricted to the glutamine/
glutamate shuttle in the brain without taking into
account the abluminal or luminal transporters of the
capillary endothelia.
Consequences for interpretation of amino acids
in practice
For patients with urea cycle disorders the results of
amino acid concentrations in physiological fluids are
mainly used for follow-up. Clinical evaluation alone
does not allow control and adaptation of the treatment
to the changing needs during development and the
variation of intake and endogenous nitrogen-load.
In addition to the clinical signs and (dietary) history
we have to evaluate the whole pattern of amino acids
and also look for decreased concentrations; consider
plasma ammonia concentration, electrolytes, urinary
orotate and also vitamin B12 and zinc because of
the restriction of natural protein; assay markers of
impaired protein synthesis before it is manifest as
delay of head and length growth (markers are trans-
thyretin and coagulation factors (short half-life) and
albumin or pseudocholinesterase (long half-life)); and
monitor alternative-pathway drugs especially in neo-
nates or when given at high doses.
In order to improve the medical decisions by the use
of biochemical parameters, one should make sure that
the results are reliable, not only by quality control
of the analyses but also by clear prescription of the
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pre-analytical procedure. The samples of the analytes
mentioned above should be obtained at the same time,
i.e. when they are at trough level, to assure safety and
avoid low concentrations being missed (and high
concentrations of essential amino acids being exagger-
ated) by postprandial absorption or prior peroral or
intravenous administration. The time delay after the
end of the last meal should be at least 3.5 h (4 h for
arginine); in practice sampling is done just prepran-
dially. If the sampling for follow-up cannot be done at
trough level, it should always be done at the same time
postprandially during the absorptive phase to minimize
the bias and allow comparison with previous results
(taking the risk of missing the endogenous decrease of
amino acid concentrations). Such results would need to
be compared with reference values established during
the absorptive phase of defined meals, but good
reference values are lacking. We are aware that this
requirement cannot always be met or that sometimes it
is not feasible for practical reasons. The minimal
requirement for adequate retrospective interpretation
is thus that the time delay between the last intake and
sampling should always be documented.
To avoid factitious hyperammonaemia the blood must
be obtained without cuffing. Capillary sampling should
be avoided because of the contamination from destroyed
tissue and even worse by massaging. All the blood
samples should be transferred to the laboratory, and
centrifuged without delay and the plasma deproteinized
and kept frozen at acid pH (column application buffer);
otherwise glutamine will decrease and so will arginine
(and ornithine will be formed by red cell arginase).
Glutamine in plasma does not reflect the concentra-
tions in brain but it is an indicator of the capacity of other
tissues to detoxify ammonia. Wilson et al (2001) showed
that with a sufficient number of patient results there is
not a good correlation between plasma ammonia and
plasma glutamine concentration since the mechanisms
determining their concentrations in plasma differ.
If the plasma glutamine concentration remains
stable, even around the upper reference limit (Shih
2003), and if the BCAA concentrations are not below
the lower reference limit and plasma ammonia not
higher than three times the upper reference limit, we
will not find cause for alarm. We would argue that
ammonia detoxification by other pathways than the urea
cycle is still adequate for the actual waste nitrogen load.
However, if glutamine concentration is increasing in
plasma, the causes of increased load and/or reduced
elimination should be closely investigated (Morris and
Leonard 1997); excessive treatment should also be
considered and the treatment strategy should be
revised if necessary (Bachmann 2007).
Looking at the course and rate of increase of plasma
glutamine and ammonia in comparison to the last
sample(s) is more informative than comparisons with
fixed upper limits for which scientific evidence is
lacking (Summar 2001). Experimental research with
in vivo models is needed to answer the question
whether concentration patterns or the course taken
by plasma concentrations of ammonia and amino acids
allow prediction of imminent saturation or inhibition
of critical steps of nitrogen export out of the brain and
the capillary endothelia as compared with uptake (for
further reading see Kanamori and Ross 2004, 2005;
Kanamori et al 1998; Pichili et al 2007). Actually we
recommend watching closely the course that plasma
ammonia, glutamine and BCAA concentrations take.
For interpretation of low BCAA concentrations in
plasma of patients with urea cycle disorders, the
following causes should be considered (and might be
combined): chronic or acute hyperammonaemia; exces-
sive phenylbutyrate administration (see below); reduced
dietary intake (excessive restriction of protein without
adequate supplementation of essential amino acids); and
infectious disease. An accurate assessment of the dietary
intake is needed for determination of the causes of low
BCAAs in plasma.
If not only BCAAs but also phenylalanine and
tyrosine concentrations are decreased in plasma
obtained preprandially, insufficient intake has to be
considered. Normal or increased phenolic amino acid
(and methionine) concentrations do not, however, rule
out insufficient intake if there is hepatic insufficiency
(fibrosis, cirrhosis).
A chronic decrease of BCAAs will likely prolong the
duration of catabolism and thus the increased endoge-
nous nitrogen load. An (increased) supplementation of
BCAAs or of natural protein despite existing hyper-
ammonaemia (usually <250 mmol/L in our experience)
might help to rule out BCAA deficiency as its cause.
Close surveillance is needed when increasing nitrogen
load in such situations to make sure that plasma
ammonia decreases. We repeatedly observed in our
laboratory that the plasma threonine concentration
overshoots upon increasing the protein supply after
excessive restriction. The mechanism leading to this
increased threonine concentrations is not clear. Threo-
nine concentration in plasma normalizes after a few
days in this instance.
The Fconsensus_ recommendation (Summar 2001) to
supply essential amino acids only in severe cases of
UCD must be questioned. In our view, special
essential amino acid mixtures (UCD\ (Milupa) or
EAM\ (SHS) for oral administration; Aminosteril
Hepa\ (Fresenius) for intravenous administration)
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which are enriched with BCAAs (without carnitine)
should be given at least when the plasma BCAAs are
decreased below the lower limit of the normal range in
order to allow anabolism independently of the severity
of the defect. Furthermore, supplementation of the
diet with essential amino acid mixtures allows restric-
tion of the intake of natural protein to 30–50% below
RDA and thus reduction of the proportion of nones-
sential amino acid intake, and the nitrogen load.
Alternative pathway therapy with phenylbutyrate
Alternative pathway therapy with phenylbutyrate (or
phenylacetate) further enhances the utilization of
leucine in liver and kidney by increased formation of
phenylbutyrylglutamine and phenylacetylglutamine,
which are excreted in urine. In vivo experiments in
humans, primates and rodents for assessing the ana-
plerosis versus cataplerosis (pyruvate dehydrogenase)
have used phenylacetate to quantitatively divert a-
ketoglutarate to phenylacetylglutamine (via glutamate
and glutamine), and this in absence of hyperammo-
naemia (Darmaun et al 1998; Hankard et al 1995;
Jones et al 1998; Owen 1998). This indicates that
cytosolic synthesis of glutamate (and BCAA consump-
tion) is raised not only by increased ammonia concen-
tration but (independently) also for compensating its
utilization for phenylbutyrylglutamine or phenylace-
tylglutamine excretion. Scaglia and colleagues (2004,
2007) have recently shown in controls and UCD
patients that upon administration of phenylbutyrate
(but not of benzoate) the patients have a selective
decrease of plasma BCAAs despite adequate dietary
intake; however, the plasma concentrations of other
essential amino acids did not change. Low BCAA
concentrations published for patients treated with
phenylacetate or phenylbutyrate (Maestri et al 1995,
1999) show that this is not just a theoretical or
experimental consideration. The findings of Scaglia
and colleagues contradict a recent report of Bhatta-
charya and colleagues (2007). These authors found in
18 adult OTC-deficient patients that sodium benzoate
was associated with low BCAA concentrations in
plasma as much as in patients treated with phenyl-
butyrate; in addition the patients had low phenylala-
nine and increased plasma concentrations of
glutamine, alanine and glycine; seven patients had a
vitamin B12 deficiency. Neither the diet nor the drug
concentrations or doses were reported in the abstract.
Thus the work needs confirmation.
We further suggest not using phenylbutyrate chron-
ically in female patients because phenylbutyrate is a
potent inhibitor of the histone deacetylases (HDAC)
and impairs NFkB activation, isoprenylation and
PPRPa and g (Xin et al 1999) as shown experimentally.
Its interference with cell cycle control is exploited in
cancer therapy (Bdifferentiation therapy^ with anticar-
cinogenic drugs) (Calvaruso et al 2001; Camacho et al
2007; Chang and Szabo 2002; Lea et al 2004; Mehnert
and Kelly 2007). Among the many side-effects of
phenylbutyrate the most worrisome is the risk of
polycystic ovaries. Wiech and colleagues reported in
1997 that the most common clinical adverse event was
amenorrhoea/menstrual dysfunction: 23% of female
UCD patients who had started their periods and were
on phenylbutyrate therapy had irregular menstrual
cycles or became amenorrhoeic (as cited by Batshaw
et al 2001). To our knowledge there is no report of such
clinical findings in females with urea cycle disorders
who have reached postpubertal age and who were not
treated with phenylbutyrate. Furthermore, this side-
effect of phenylbutyrate is listed on package inserts
and should, in our view, not be taken lightly. The
most likely cause appears to be histone hyperacetyla-
tion by phenylbutyrate; this same side-effect was also
described for long-term valproate application (Isoja¨rvi
et al 1993). Valproate is a similar HDAC inhibitor
(Blaheta and Cinatl 2002; Gottlicher 2004; Phiel et al
2001). Polycystic ovaries and hyperandrogenism were
found in 80% of women on chronic valproate treat-
ment before 20 years of age (43% with menstrual
disturbances).
Careful controlled studies are needed to assessing
side-effects of long-term application of phenylbutyrate
in comparison, for example, with sodium benzoate as
substrates for alternative pathway therapy. Meanwhile,
for reasons of safety and to avoid additional BCAA
consumption, we prefer to use benzoate, which is
almost as efficient as phenylbutyrate; we would add
intravenous phenylacetate only during crisis situations
if benzoate rose to toxic levels above 2 mmol/L (e.g.
in neonates).
Neurotransmitter disorders
Extrapolation of the PKU model does not work in
neurotransmitter disorders. I began to realize this
when we found an increased CSF/plasma ratio of
glycine (0.31) in a patient with neonatal nonketotic
hyperglycinaemia (NKH) (Bachmann et al 1971). Post
mortem we found very high concentrations of glycine
in cerebellum (11 mmol/kg wet wt; controls: 1.8 and
2.1) and cerebrum (4 mmol/kg wet wt). Reference
values of autopsied adults (mean (SEM) mmol/kg
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wet wt) are: cerebellum 2.07 (0.39) and cortex 1.75
(0.15) (Perry et al 1971). The increases in our patient
were thus 5-fold and 2-fold respectively. Our findings
in NKH have been confirmed in vitro (Perry et al
1975) and in vivo (Novotny et al 2003). The compar-
ison by Huisman and colleagues (2002) of in vivo
(proton MRS) and ex vivo (ion-exchange chromatog-
raphy) concentrations of glycine in different parts of
the brain of a patient with NKH who died at 9 days of
age is reassuring: the authors showed that the methods
correlated well.
We knew in 1971 about glycinergic transmission but
did not dare to use its inhibitor (strychnine) for
treatment. Without success, we used means to lower
glycine in plasma including benzoate. It remains open
whether or when lowering glycine in plasma is useful
in NKH patients. While in some patients it has been
successful, in others it failed. The malfunctioning
glycine cleavage system in CNS is well isolated from
the peripheral circulation by the blood–brain barrier.
The contribution of glycine taken up from plasma
through the blood–brain barrier is considered to be
minimal compared with its synthesis within the brain.
In Fketotic hyperglycinaemia_ (propionic or methylma-
lonic acidaemia) CSF/plasma glycine ratios have been
considered not to be frankly increased, despite an
increase of glycine in plasma comparable to that in
NKH, if pitfalls such as valproate therapy are avoided
(Applegarth and Toone 2001; Korman and Gutman
2002). Harris and colleagues reported a CSF/plasma
ratio of 0.16 in a patient with propionic acidaemia
(Harris et al 1981); the CSF phenylalanine or tyrosine
concentrations were not reported, however, and thus
blood contamination cannot be excluded. More data
are needed to clarify whether the CSF/plasma ratio of
glycine really allows for differentiation between non-
ketotic and Fketotic_ hyperglycinaemias.
In theory, lowering glycine outside of the brain by
administration of high doses of sodium benzoate which
is detoxified in liver to hippurate (benzoylglycine)
seems not to be relevant. Still, in some patients sodium
benzoate therapy has been considered to be useful.
Could it be that the application of benzoate or
hippurate stimulates the sodium-dependent transport-
ers of the abluminal membrane of the brain capillary
endothelia (or of astrocytes) and thus the export of
extracellular glycine out of the brain?
It is now known that glycine is a neurotransmitter in
strychnine-sensitive glycinergic inhibitory synapses in
spinal cord and medulla as well as an excitatory co-
agonist in strychnine-insensitive glutamatergic (NMDA)
synapses in the CNS and spinal cord. Furthermore, it
is a neurotransmitter in amacrine cells of the retina
(strychnine-sensitive).
Treatment should allow reduction of the effects of
glycine in both the inhibitory synapses and the
excitatory NMDA receptors. Treatments of NKH
patients with blockers of inhibitory synapses such as
strychnine or with NMDA receptor blockers have
been tried separately; results were discrepant and
hence nonconclusive (Gitzelmann et al 1978; Tada
and Kure 2005; von Wendt et al 1980). To our
knowledge the treatments have not been combined,
although our understanding is that this might be tried,
provided NKH has not irreversibly harmed the CNS
prenatally. A delay of myelination and disturbed
cytoarchitecture have been described (Bachmann et al
1971; Diezel and Martin 1966). Cerebral malforma-
tions have also been reported especially in patients
with neonatal presentation (Tada and Kure 2005).
During embryonic development, glycinergic synap-
ses are expressed early. Postnatally, the activation of
the glycine receptors leads to opening of their anion
channel (Clj) and to hyperpolarization. However,
during embryonic and fetal life the chloride concen-
tration in nerve cells is high until the Clj/K+ cotrans-
porter is expressed around birth. Hence in embryos the
opening of the intrinsic anion channel of the glycine
receptors leads to an efflux of chloride from the
postsynaptic cells and thus to depolarization of target
neurons by glycine (Eulenburg et al 2005). It is not
clear whether this leads to prolonged excitation of
postsynaptic neurons during embryonic development
and to malformations in NKH.
If, after taking account of this caveat, a combined
treatment by inhibitors of strychnine-sensitive glyciner-
gic receptors and of NMDA receptors is considered, the
drug effects should be monitored to assure an effective
dosage. Data on glycine concentrations in autopsied
cerebral or cerebellar homogenates or in vivo in
patients do not allow a decision on whether treatment
is effective in the synapses since concentrations in the
presynaptic vesicles of glutamatergic neurons or in the
synaptic cleft are thought to be physiologically 100
times higher than in brain homogenates. An average
concentration of the compartments does not make sense.
In fact, we ignore the relevant pre- and postsynaptic
glycine (and D-serine) concentrations in NKH patients;
in addition, there might be adaptive changes of the
(N-glycosylated!) glycine transport proteins transport-
ing glycine into and out of synapses and glia. Interest-
ingly, Gly-transporter1 knockout mice show symptoms
similar to NKH, while Gly-transporter2 knockouts
resemble hypoglycinergic hyperekplexia (for review
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see Eulenburg et al 2005). To our knowledge, a
pathophysiological role of glycine transport has not
been studied in N-glycosylation defects.
Clinical assessment of the effect of blockers like
strychnine on medullar (pontine) neurons, or on ama-
crine cell function by electroretinography, seems feasi-
ble. Concerning the control of NMDA-blockers,
Whitehead and colleagues (2004) showed by micro-
dialysis of dorsal spine cord in rats that glycinergic co-
activation led to an increase of citrulline concentration
of 50% (basal value 6 pmol/20 ml dialysate) as a product
of NOS in the dialysate. It was measured by HPLC with
fluorometric detection of the derivatized citrulline,
From research in hyperammonaemic encephalopathy
it is well known that glutamatergic hyperactivity leads
to a calmodulin-dependent NOS activation in NMDA
receptors; NO activates soluble guanylate cyclase
(which can be blocked by sildenafil). One can imagine
that sensitive citrulline assays in CSF might help to
monitor the effects of NMDA-blockers in NKH (and
urea cycle disorders?) provided the CSF concentration
reflects intracellular changes as does the dialysate.
Conclusions
Awareness of basic knowledge in physiological and
pathological biochemistry is needed to avoid pitfalls
and appreciate the limits of interpretation imposed on us
when we try to understand patterns of amino acids in
plasma or other markers of intermediary metabolism.
The gap between knowledge acquired in basic research
on the function of isolated proteins or cells in vitro and
the poor resolution and sensitivity of in vivo imaging
systems indicates that translational research is needed.
Actually, the advantage of localization by quantitative in
vivo imaging methods is compromised by the brain
sample volumes of millilitres and by the low sensitivity
limited to quantifying solute concentration, usually
above 0.1 mmol/L. Such samples are equivalent to
homogenates of different structures, cell types and
organelles. They are useful for diagnoses of gross
changes, despite averaging of concentrations differences,
which can be 1000-fold between compartments. To
bridge this gap, coordinated in vitro, ex vivo and in vivo
research on relevant pathways is needed: e.g. quantifi-
cation coupled to localization of metabolites, RNA and
protein expression at tissue and cellular level from
mixed brain cell culture systems or ex vivo from
experimental animals with defined gene defects and
feeding conditions. The goal would be a functional
anatomy and cytology at high sensitivity and high
resolution. Such results could be compared for valida-
tion with in vivo investigations on patients and controls
for defined clinical problems in inherited diseases of
intermediary metabolism. Careful planning with accept-
ed protocols and collection of information in interna-
tional registries with predefined minimal information on
patients and their data would help to concentrate the
efforts on these rare disorders with much interindividual
variance at all levels. The hope is that proceeding in a
concerted way (e.g. within the SSIEM) will result in
more effective prevention and treatment of inborn
errors of metabolism, to the benefit of the patients.
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